C4 Therapeutics Inc. has released a corporate presentation detailing progress across its pipeline of targeted protein degrader medicines. The presentation highlights the advancement of cemsidomide, an IKZF1/3 degrader, which has completed Phase 1 dose escalation in multiple myeloma (MM) and is being evaluated in non-Hodgkin's lymphoma (NHL). Plans include presenting full Phase 1 data at the International Myeloma Society Annual Meeting and initiating a Phase 2 trial of cemsidomide in combination with dexamethasone. Additionally, C4 Therapeutics is utilizing Phase 1 data from its CFT8919 EGFR L858R program to inform global clinical development strategies. The company also announced it will not advance CFT1946 beyond Phase 1 and is seeking partnership opportunities for its BRAF program. The pipeline includes ongoing research targeting pathways such as IL-23/IL-17, Type 1 IFN, MAPK, PI3K/AKT, and NF-κB, with a focus on both oncology and non-oncology indications. C4 Therapeutics continues to pursue collaborations, including a partnership with Pfizer, which will supply elranatamab for an upcoming Phase 1b trial. You can access the full presentation through the link below: [Full Presentation](https://docs.publicnow.com/3CE77CEA538DC349B7BDA965266C8C8BC59AD8B7)